

# Reducing Risk and Improving Outcomes:

## CDK4/6 Inhibitors in Early and Advanced HR+/HER2- Breast Cancer



15 May 2025



Room 5,  
ICM – International Congress  
Center Messe Munich



17:45–18:45 CEST



## SPEAKERS



**Peter Fasching (chair)**  
University Hospital Erlangen  
Comprehensive Cancer Center



**Hope Rugo**  
University of California San  
Francisco Helen Diller Family  
Comprehensive Cancer Center



**Fatima Cardoso**  
ABC Global Alliance

## AGENDA

- Welcome and introduction
- Evolution of risk in patients with HR+ EBC
- Patient 1: Node-positive EBC
- Patient 2: Node-negative EBC and high-risk characteristics
- Patient 3: Clinically aggressive ABC
- Key takeaways and live Q&A

This symposium is organized and funded by Novartis Pharma AG in the context of the ESMO BC Congress 2025 in Munich, Germany.

This medical education event is solely intended for non-US physicians and pharmacists only. This scientific information may include data/information on investigational uses of compounds/drugs that have not been approved by regulatory authorities.

Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country